Requirements for comprehensive pharmacogenetic genotyping platforms

Pharmacogenomics

Volumn 17, Issue 8, 2016, Pages 917-924

  Lauschke, Volker M ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

clinical implementation; genetic variation; personalized medicine; pharmacogenomics; precision medicine

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COMPUTER ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; INTERMETHOD COMPARISON; NEXT GENERATION SEQUENCING; PHARMACOGENETICS; PHENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; PROCEDURES; RETROSPECTIVE STUDY;

GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHARMACOGENETICS; PHENOTYPE; RETROSPECTIVE STUDIES;

EID: 84976503094     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0023     Document Type: Article

References (54)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol. 30, 1117-1124 (2012).
3. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 13, 1-11 (2012).
4. Pirmohamed M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18, 820 patients. BMJ 329, 15-19 (2004).
5. Davies EC, Green CF, Taylor S et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patientepisodes. PLoS ONE 4, e4439 (2009).
6. Gallagher RM, Mason JR, Bird KA et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS ONE 7, e50127-e50128 (2012).
7. Thiesen S, Conroy EJ, Bellis JR et al. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children-a prospective observational cohort study of 6, 601 admissions. BMC medicine 11, 237 (2013).
8. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 526, 343-350 (2015).
9. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical Pharmacol. Ther. 90, 625-629 (2011).
10. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome p450 2d6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95, 376-382 (2014).
11. Wilke RA, Ramsey LB, Johnson SG et al. The clinical pharmacogenomics implementation consortium: cpic guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2009).
12. Pratt VM, Zehnbauer B, Wilson JA et al. Characterization of 107 genomic dna reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1. J. Mol. Diagn. 12, 835-846 (2010).
13. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65 (2012).
14. Tennessen JA, Bigham AW, O'Connor TD et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337, 64-69 (2012).
15. Nelson MR, Wegmann D, Ehm MG et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14, 002 people. Science 337, 100-104 (2012).
16. Li Y, Vinckenbosch N, Tian G et al. Resequencing of 200 human exomes identifies an excess of low-frequency nonsynonymous coding variants. Nat. Genetics 42, 969-972 (2010).
17. Marth GT, Yu F, Indap AR et al. The functional spectrum of low-frequency coding variation. Genome Biology 12, R84 (2011).
18. Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genomics 25, 584-594 (2015).
19. Gordon AS, Tabor HK, Johnson AD et al. Quantifying rare, deleterious variation in 12 human cytochrome P450 drugmetabolism genes in a large-scale exome dataset. Hum. Mol. Genetics 23, 1957-1963 (2014).
20. Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes and nuclear receptors can be important determinants of inter-individual differences in drug response. Genet Med. doi:10.1038/gim.2016.33 (2016) (Epub ahead of print).
21. Wetterstrand KA. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). www.genome.gov/sequencingcosts
22. Sboner A, Mu X, Greenbaum D, Auerbach RK, Gerstein MB. The real cost of sequencing: higher than you think! Genome Biol. 12, 125 (2011)
23. Rasmussen-Torvik LJ, Stallings SC, Gordon AS et al. Design and anticipated outcomes of the eMERGE-PGx Project: a multicenter pilot for pre-emptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther. 96, 482-489 (2014).
24. Gordon AS, Fulton RS, Qin X et al. PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet. Genom. 26(4), 161-168 (2016).
25. Bielinski SJ, Olson JE, Pathak J et al. Pre-emptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clinic Proceedings 89, 25-33 (2014).
26. Browning SR, Browning BL. Haplotype phasing: existing methods and new developments. Nat. Rev. Mol. Cell. Biol. 12, 703-714 (2011).
27. Rao Y, Hoffmann E, Zia M et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58, 747-755 (2000).
28. McDonagh EM, Wassenaar C, David SP et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet. Genomics 22, 695-708 (2012).
29. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25, 534-553 (2013).
30. Qiao W, Yang Y, Sebra R et al. Long-read single-molecule realtime (SMRT) full gene sequencing of cytochrome P450-2D6 (CYP2D6). Hum. Mutation, 37, 315-323 (2016).
31. Ammar R, Paton TA, Torti D, Shlien A, Bader GD. Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000 Research 4, 17 (2015).
32. Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends Pharmacol. Sci. 37, 85-86 (2016).
33. Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. 97, 10483-10488 (2000).
34. Scott SA, Martis S, Peter I et al. Identification of CYP2C194B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenom. J. 12, 297-305 (2012).
35. Liu M, Watson LT & Zhang L. Predicting the combined effect of multiple genetic variants. Hum. Genomics 9(1), 18 (2015).
36. Cong L, Ran FA, Cox D et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
37. Kleinstiver BP, Prew MS, Tsai SQ et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481-485 (2015).
38. Koike-Yusa H, Li Y, Tan E-P, Velasco-Herrera MDC, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267-273 (2013).
39. Zhou Y, Zhu S, Cai C et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487-491 (2014).
40. Shalem O, Sanjana NE, Hartenian E et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
41. Wang T, Birsoy K, Hughes NW et al. Identification and characterization of essential genes in the human genome. Science 350, 1096-1101 (2015).
42. Poste G. Bring on the biomarkers. Nature 469, 156-157 (2011).
43. Sanderson S, Zimmern R, Kroese M et al. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genetics Med. 7, 495-500 (2005).
44. Chung W-H, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486-486 (2004).
45. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genetics Med. 13, 987-995 (2011).
46. Kalman LV, Agúndez J, Appell ML et al. Pharmacogenetic allele nomenclature: International Workgroup recommendations for test result reporting. Clin. Pharmacol. Ther. 99, 172-185 (2016).
47. Hess GP, Fonseca E, Scott R, Fagerness J. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genetics Res. 97, e13 (2015).
48. PharmGKB. www.pharmgkb.org/page/cpicTermProject
49. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm. Prac. 25, 417-427 (2012).
50. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 13, 378-388 (2013).
51. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 296, 212-215 (2006).
52. Elias S, Annas GJ. Generic Consent for Genetic Screening. N. Eng. J. Med. 330, 1611-1613 (1994).
53. Ubiquitous Pharmacogenomics (U-PGx). http://upgx.eu
54. Forbes SA, Beare D, Gunasekaran P et al. COSMIC: exploring the world & knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).